WeVote
Log In

Bill

Bill

S 664

Relates to assessment and taxation of lessees and users of certain tax exempt property

2025 Regular Session Introduced by Andrew Gounardes and 2 co-sponsors

The bill creates a non-lapsing Cancer Research Fund funded at $10M/year from tobacco taxes to support general and pediatric cancer research grants.

DELIVERED TO ASSEMBLY
0
WeVote Research Nonpartisan
Bill Summary · S 664

Summary — S.664 (2025): Cancer Research Fund — increases tobacco-tax allocation; creates dedicated non‑lapsing fund

Purpose

S.664 increases and secures annual tobacco-tax support for the New Jersey Commission on Cancer Research (NJCCR). It raises the statutorily directed share of cigarette and other tobacco products tax revenues from $1,000,000 to $10,000,000 and establishes a dedicated, non‑lapsing Cancer Research Fund to ensure those monies are used for cancer research grants and contracts.

Key provisions

  • Raises the annual deposit to the Cancer Research Fund from $1,000,000 to $10,000,000 (tax revenues pursuant to section 301 of P.L.1948, c.65).
  • Replaces the existing lapsing Cancer Research Fund with a non‑lapsing, revolving Cancer Research Fund housed in the Department of the Treasury.
  • Specifies permitted uses: monies (and interest) are to be used exclusively for grants and contracts for cancer research projects authorized and approved by the NJCCR.
  • Funding priorities: at least $5,000,000 must be used for general cancer research and at least $5,000,000 for pediatric cancer research.
  • Treasurer custodianship: State Treasurer is custodian; disbursements require vouchers signed by the NJCCR chair or designee. Fund monies are to be invested by the Division of Investment; interest credited to the Fund.
  • Repeals section 8 of P.L.1983, c.6 (statutory cleanup associated with the commission).
  • Effective immediately upon enactment.

Who is affected / likely impacts

  • New Jersey Commission on Cancer Research: receives a larger, more stable funding stream and increased ability to award research grants and contracts.
  • Cancer research community and pediatric oncology programs: expanded grant funding, including guaranteed pediatric allocation.
  • Patients and communities: targeted funding is intended to support research on causes, prevention, treatment and palliation of cancers and to reduce disparities in access to clinical trials and care among racial/ethnic minority and vulnerable populations.
  • State budget process: converting to a non‑lapsing fund reduces the ability to sweep these revenues into the General Fund via annual appropriations, making funding more predictable.

Fiscal and procedural notes

  • Dollar amounts: $10,000,000 annual deposit; minimum allocations of $5,000,000 each to general and pediatric research.
  • Legislative status (from provided materials): introduced Feb 20, 2025; reported favorably by Senate Health, Human Services and Senior Citizens Committee (May 19, 2025); passed the Senate May 28, 2025; delivered to the Assembly and referred to committee(s) (Real Property Taxation per the record). A hearing was scheduled for June 17, 2025.
  • The bill’s sponsor list in the committee report identifies NJ Senators Robert W. Singer and Anthony M. Bucco (plus multiple co‑sponsors). Note: the provided packet contains unrelated text and sponsor entries (including materials from other jurisdictions and chambers); those portions appear to be mismatched and are not part of the New Jersey S.664 substantive text.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.